BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to host investor webcast showcasing momentum across solid tumor pipeline SAN CARLOS, Calif. — BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.